# Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease

> **NCT03618108** · PHASE2 · TERMINATED · sponsor: **Cadrock Pty. Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Coronary Heart Disease
- Chlamydophila Pneumoniae Infections

## Interventions

- **DRUG:** Doxycycline Capsule
- **DRUG:** Azithromycin Capsule
- **DRUG:** Rifabutin Oral Capsule
- **DRUG:** Placebo oral capsule
- **DRUG:** Placebo Oral Tablet
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03618108
- **Lead sponsor:** Cadrock Pty. Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-04
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** COVID-19
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618108, "Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03618108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*